Angiocrine Bioscience, Inc.
- Engineered endothelial cell (E-CEL) therapies
Angiocrine Bioscience is an innovative, early clinical stage biotechnology company located in San Diego, California, harnessing the power of its proprietary engineered endothelial cells for treating numerous life-threatening hematology and oncology conditions, as well as, in the field of organ and tissue regeneration. Angiocrine is at the front line in the next great medical revolution of utilizing living cells to improve the health and quality of life for patients in need.
Angiocrine’s core technology is licensed from Weill Cornell Medicine and was invented and developed by Professor Shahin Rafii, MD. His work related to Angiocrine technology has been published in numerous peer-reviewed journals, including Cell Stem Cell, Nature, Cell, and Blood.